Drug Profile
Research programme: anti-CEA fusion proteins - Cancer Research Technologies/Novozymes/UCL
Alternative Names: Anti-CEA scFv fusion proteins; MFE 23-albumin fusion protein; MFE-23Latest Information Update: 01 Aug 2012
Price :
$50
*
At a glance
- Originator Cancer Research Technology; University College London
- Developer Cancer Research Technology; Novozymes Delta; University College London
- Class Albumins; Immunoglobulin fusion proteins; Immunoglobulin Fv fragments; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 01 Aug 2012 No development reported - Early research for Solid tumours in United Kingdom (Parenteral)
- 11 Sep 2007 Early research in Solid tumours in United Kingdom (Parenteral)